Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative CCRT + Anti-PD-1 in High-Risk LA HNSCC
NCT06170710Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Dec 2023
- Primary completion
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, nivolumab, tislelizumab, camrelizumab, sintilimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Dec 2023; status: recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06170710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06170710.